Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Common Equity (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Common Equity readings, the most recent being $53.5 million for Q4 2025.

  • On a quarterly basis, Common Equity rose 284.81% to $53.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $53.5 million, a 284.81% increase, with the full-year FY2025 number at $53.5 million, up 284.81% from a year prior.
  • Common Equity hit $53.5 million in Q4 2025 for Aligos Therapeutics, down from $71.8 million in the prior quarter.
  • In the past five years, Common Equity ranged from a high of $217.0 million in Q3 2021 to a low of -$29.0 million in Q4 2024.
  • Median Common Equity over the past 5 years was $97.0 million (2023), compared with a mean of $103.7 million.
  • Biggest five-year swings in Common Equity: crashed 131.47% in 2024 and later skyrocketed 284.81% in 2025.
  • Aligos Therapeutics' Common Equity stood at $184.7 million in 2021, then tumbled by 43.76% to $103.9 million in 2022, then decreased by 11.38% to $92.1 million in 2023, then plummeted by 131.47% to -$29.0 million in 2024, then skyrocketed by 284.81% to $53.5 million in 2025.
  • The last three reported values for Common Equity were $53.5 million (Q4 2025), $71.8 million (Q3 2025), and $101.9 million (Q2 2025) per Business Quant data.